• In early June 2026, HCA Healthcare agreed to acquire The College of Health Care Professions, a Texas-based educator serving over 8,000 students annually across 10 campuses and online, deepening a long-standing partnership centered on clinical training and career placement.
• This move expands HCA’s direct role in healthcare education and workforce development, potentially strengthening its talent pipeline and operational capabilities across its hospital network.
• Next, we’ll examine how acquiring The College of Health Care Professions could influence HCA Healthcare’s investment narrative around growth and efficiency.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

HCA Healthcare Investment Narrative Recap

To own HCA Healthcare, you need to believe its large hospital footprint, cost discipline and capital returns can outweigh policy uncertainty and reimbursement pressure. Right now, the most important near term swing factor remains the evolving federal and state funding backdrop; the CHCP acquisition does not meaningfully change that, but it may modestly support HCA’s long term staffing and wage picture, which ties back to margin risk and the company’s ability to fund its sizeable capital and debt obligations.

The announced purchase of The College of Health Care Professions fits alongside HCA’s existing expansion in emergency rooms and outpatient sites, as well as its AI and resiliency initiatives. While the CHCP deal is about education capacity, investors may see it in the same bucket as HCA’s cost and efficiency programs, which aim to offset payer mix headwinds and keep margins resilient if exchange and Medicaid trends become more challenging.

Yet behind HCA’s expansion story, the growing share of uninsured admissions and pressure on exchange economics is something investors should be aware of as...

HCA Healthcare's narrative projects $88.4 billion revenue and $7.6 billion earnings by 2029.

Uncover how HCA Healthcare's forecasts yield a $510.95 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming HCA could reach about US$90.7 billion of revenue and US$7.8 billion of earnings by 2029, which is far more upbeat than the baseline view and sits uncomfortably beside rising uninsured volumes and ACA exchange headwinds; depending on how deals like CHCP play out, you may find your own expectations sitting closer to one narrative or the other.

Explore 3 other fair value estimates on HCA Healthcare - why the stock might be worth just $510.95!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your HCA Healthcare research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free HCA Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate HCA Healthcare's overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.